Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days

We compared three fludarabine-based regimens for systemic sclerosis patients with a high-risk cardiac phenotype that according to EBMT criteria would be a contraindication for a high-dose cyclophosphamide (200 mg/kg) transplant regimen. All three regimens included fludarabine, ATG, and cyclophospham...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2021-01, Vol.56 (1), p.50-59
Hauptverfasser:	Burt, Richard K., Han, Xiaoqiang, Quigley, Kathleen, Arnautovic, Indira, Shah, Sanjiv J., Lee, Daniel C., Freed, Benjamin H., Jovanovic, Borko, Helenowski, Irene B.
Format:	Artikel
Sprache:	eng
Schlagworte:	13 13/100 692/308/2779/109/1940 692/699/249/1313 Autoimmune diseases Blood transfusion Cardiovascular diseases Care and treatment Cell Biology Complications and side effects Cyclophosphamide Dosage and administration Erythrocytes Fludarabine Hematology Hematopoietic stem cells Immunoglobulins Infections Internal Medicine Intravenous administration Medicine Medicine & Public Health Monoclonal antibodies Neutropenia Phenotypes Prevention Public Health Respiratory tract Respiratory tract diseases Risk Risk factors Rituximab Safety Scleroderma Scleroderma (Disease) Stem cell transplantation Stem Cells Systemic scleroderma Systemic sclerosis Testing Transplantation Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!